Case Studies

How a Specialist Drug Maker Ensures that its Travel Drug Program is Best in Class

Posted by |


In order to compete more effectively in the market, a maker of specialist drugs for chronic conditions wanted to ensure that it offered a best-in-class support program for its patients when they traveled outside their home countries.


Despite an almost complete absence of public information about this highly nuanced market niche, Fuld & Company was able to gain deep insights into the travel drug program of the client’s closest competitor.


After quickly synthesizing what little public information was available, the Fuld team met the engagement’s unique challenges in the only way possible. We conducted exhaustive primary research with stakeholders in multiple countries and mapped the program of the client’s closest competitor. As a result, we were able to paint a complete picture, thereby providing the client with the ability to compare its own practices to those of the competitor.

Result + Benefits

Given so many complexities and nuances, the client gained valuable insights about all of the stakeholders involved, and about the many different practices in the various target countries – insights that can be leveraged to fine-tune the company’s own program. This was something it could not have learned in such an opaque and complex market without Fuld’s assistance. Now, instead of blindly throwing resources at the program, the company can confidently stay on course.

Download PDF

Tags: , , , ,

Related Resources

Read More

Sustainable innovation in the polymer industry

Delivering sustainable innovation How we helped a leading industrial polymer manufacturer cut 1.5 years off its R&D timeline… and win […]

Read More

Leveraging Machine Learning in Customer Sentiment Analysis

In a highly competitive market, staying ahead of customer expectations is critical for any manufacturer. A leading US plumbing fixture […]

Read More

Healthcare and Pharma Competitive Intelligence Dashboard

A US-based healthcare company wanted to explore its options for a clinical drug development strategy that would minimize its time […]

Subscribe to our mailing list for our latest updates: